Zacks.com on MSN19h
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMSSanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...
A breakthrough treatment is making a huge difference for stroke survivors, improving hand and arm function, and their quality ...
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
SER-155 is an oral, 16-strain microbiome therapeutic that works by decolonizing gastrointestinal pathogens, strengthening the epithelial barrier, and inducing immune tolerance.
Kessler scientists' trial set to evaluate non-invasive brain stimulation for upper-extremity disability post-stroke, ...
The Irish News on MSN10d
Medical breakthrough as therapy unveiled for ‘untreatable’ debilitating illnessA man who does not wish to be named became the first person treated in the global trial a few weeks ago, receiving the ...
Collaboration between Bascom Palmer Eye Institute and Provectus BiopharmaceuticalsKNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback